Skip to content

Evaluation of the Effects of the cooperative General Practitioner-Specialist Management Model for Inpatients With Type 2 Diabetes in the Community: a Randomized Controlled Trial

Construction and Evaluation of the Cooperative General Practitioner-Specialist Management Model for Patients With Type 2 Diabetes Based on the Integration of Prevention and Treatment StrategyConstruction and Evaluation of the Cooperative General Practitioner-Specialist Management Model for Patients With Type 2 Diabetes Based&#32

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062541
Enrollment
Unknown
Registered
2022-08-11
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

intervention group :Cooperative General Practitioner-Specialist Management
control group :No intervention was taken, and general practitioners routinely treated and followed up patients according to clinical guidelines.

Sponsors

Baoan Central Hospital of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have been diagnosed with type 2 diabetes for at least 1 year according to the diabetes diagnostic criteria formulated by the World Health Organization, and have been hospitalized in the department of endocrinology for diabetes during the recruitment period; 2. Male or female residents aged 18-75 years; 3. HbA1c measured within 6 months before enrollment was 7.0%-10.0%, and has been received hypoglycemic therapy for at least 8-12 weeks before admission; 4. Willingness to cooperate with the physician in completing all examinations during hospitalization; 5. Lived in the catchment and have established health records for at least 6 months, and have no plans to move out at present; 6. Sign the informed consent and participate in the study voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 diabetes, LADA, gestational diabetes, patients with extremely poor islet function (fasting C-peptide < 0.1ng/ml) and patients with special type of diabetes; 2. Patients with serious complications (such as Stage G5 of diabetic nephropathy, severe loss of vision or blindness due to diabetic retinopathy and patients without self-care ability due to diabetic foot amputation). 3. Patients who suffered from serious mental illness or late stage of other serious diseases (such as malignant tumors, acute cardiovascular disease (like stroke, myocardial infarction), serious liver insufficiency, patients with history of diabetic ketoacidosis, patients with alcohol or drug abuse or dependence and patients with a life expectancy of less than three years; 4. Patients used continuous glucose monitoring (CGM) in the past 3 months before this admission; 5. Patients with cognitive impairment, or patients unable to use mobile phones to answer calls.

Design outcomes

Primary

MeasureTime frame
change in glycated haemoglobin (in the form of HbA1c);

Secondary

MeasureTime frame
Changes in fasting blood glucose;Blood lipids;Fasting C-peptide;Blood Pressure;BMI (Body Mass Index);Incidence of diabetic retinopathy;Renal function;Incidence of macrovascular complications(carotid, cardiovascular);Diabetes self-management ability scores;Depression scores;Diabetes distress scores;The diabetes empowerment scores;Diabetes social support scores;Use of health services for patients with diabetes;

Countries

China

Contacts

Public ContactDeng Ying

Baoan Central Hospital of Shenzhen

36962647@qq.com+86 13823188425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026